ArticleOncoTargets and therapy2026
Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: A Single-Center Case Series of Five Patients.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse sclerosing variant papillary thyroid carcinoma (DSVPTC) is a rare subtype of papillary thyroid carcinoma characterized by diffuse intrathyroidal involvement and frequent cervical lymph node metastasis. This study aims to delineate the clinicopathologic features, treatment outcomes, and recurrence patterns of DSVPTC. Methods: We retrospectively reviewed five patients with histopathologically confirmed DSVPTC treated at Zibo Central Hospital between 2009 and 2025. Follow-up data were collected until December 30, 2025. Results: Patients were aged 22-54 years (median: 41 years) and 60% (3/5) were female. Hashimoto's thyroiditis was present in 80% (4/5). All patients presented with diffuse microcalcifications on ultrasound (100%, 5/5). Thyroid FNA was performed in 80% (4/5) and all aspirates were Bethesda category VI. Cervical lymph node metastasis was observed in all patients: central compartment in 100% (5/5) and lateral neck in 60% (3/5). TNM staging (8th edition) included: pT1aN1aM0 (n=1), pT1aN1bM0 (n=1), pT3bN1aM0 (n=1), pT3bN1bM0 (n=2). According to ATA risk stratification, 3 patients were classified as high risk and 2 as intermediate risk. All patients underwent total thyroidectomy with bilateral central neck dissection. Lateral neck dissection was performed in 3 patients with radiologic evidence of lateral nodal disease. All patients received TSH suppression therapy (TSH <0.1 mIU/L) and two courses of I-131 therapy (100 mCi per course) at 3 and 6 months postoperatively. With a median follow-up of 2 years (range: 1-16 years), structural recurrence occurred in 2 patients (40%, 2/5) in the ipsilateral lateral neck at 1 and 4 years, respectively. No distant metastasis or disease-specific death occurred. Conclusion: In this small series of five patients, DSVPTC commonly presented as a nodule-negative "snowstorm" microcalcification phenotype with high nodal burden. Despite aggressive multimodal therapy including total thyroidectomy, TSH suppression, and scheduled radioiodine, lateral neck recurrence occurred in 40% of patients. Meticulous preoperative lateral neck assessment and long-term imaging-based surveillance remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.